Menu Search
Equities

SinoMab BioScience Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
3681:HKG.HS

SinoMab BioScience Ltd

Actions
  • Price (HKD)1.91
  • Today's Change0.02 / 1.06%
  • Shares traded1.52m
  • 1 Year change+73.64%
  • Beta0.2740
Data delayed at least 15 minutes, as of Feb 16 2026 02:40 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

SinoMab BioScience Ltd is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE) and its product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is also developing drugs such as SM17, which has the potential to treat atopic dermatitis (AD), asthma, idiopathic pulmonary fibrosis (IPF) and other immune diseases, and SN1011, which targets systemic lupus erythematosus (SLE), pemphigus, multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD).

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-163.29m
  • Incorporated2001
  • Employees61.00
  • Location
    SinoMab BioScience LtdUnits 303 and 305 to 307No.15 Science Park West AvenueHong Kong Hong KongHKG
  • Phone+852 34269833
  • Websitehttps://www.sinomab.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.